Christopher Cannon Shares A Study Showing No Benefit When Adding an Antiplatelet to Anticoagulant in Stroke with AF and Atherosclerosis
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared on LinkedIn:
”Small randomized trial showing no benefit, and increased bleeding when adding an antiplatelet to anticoagulant in those with stroke , atherosclerosis and AF.”
Read the full article in JAMA Neurology.
Article: Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis. A Randomized Clinical Trial
Authors: Shuhei Okazaki, Kanta Tanaka, Yukako Yazawa, Ryosuke Doijiri, Masatoshi Koga, Masafumi Ihara, Shiro Yamamoto, Kenji Kamiyama, Yuko Honda, Kazutaka Uchida, Takeshi Yoshimoto, Koko Asakura, Katsuhiro Omae, Kenta Tanaka, Hirotada Maeda, Haruko Yamamoto, Teruyuki Hirano, Kazunori Toyoda, Yasuyuki Iguchi, Teruo Noguchi, Yasushi Okada, Kazuo Kitagawa, Nobuyuki Sakai, Hiroshi Yamagami
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia